Aurobindo Gets Tentative US OK For Combination Tablet
March 31 2009 - 5:31AM
Dow Jones News
India's Aurobindo Pharma Ltd. (524804.BY) said Monday it has
received tentative approval from the U.S. Food and Drug
Administration to manufacture and sell generic combination drug
emtricitabine/tenofovir disproxil fumarate tablets.
Aurobindo has received the approval for the tablets in
200-milligram and 300-mg doses, it said in a filing to the Bombay
Stock Exchange.
The tablets, which are used for the treatment of HIV-1 infection
in adults, are the generic equivalent of Gilead Sciences Inc.'s
(GILD) truvada, the company said.
-By Ameya Karve; Dow Jones Newswires; +91-22-22884212-18;
ameyaanil.karve@dowjones.com